SALARIUS PHARMACEUTICALS INC SLRX 深 滬
已收盤 10-31 16:00:00 美东时间
3.89
+0.050
+1.30%
華盛通- 最 高3.94
- 今 開3.94
- 成交量 1.91万股
- 最 低 3.7713
- 昨 收 3.84
- 總市值 367.45万
- 52周最高 108.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.1601
- 委 比 81.82%
- 總股本 94.46万
- 歷史最高 44445.00
- 量 比 0.33
- 振 幅 4.39%
- 歷史最低 3.7713
- 每 手 1
- 風險率 9.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Salarius Pharmaceuticals Approves CEO Bonus for Merger
Salarius Pharmaceuticals ( ($SLRX) ) has shared an announcement. On October 21,...
10-22 00:18
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Salarius Pharmaceuticals (Nasdaq: SLRX) has regained compliance with Nasdaq's listing requirements, marking a key step toward its merger with Decoy Therapeutics. The merger, announced in January 2025, combines Salarius' oral small molecule protein degrader SP-3164 with Decoy's peptide conjugate therapeutics platform. The combined company, named Decoy Therapeutics, aims to advance Decoy's pipeline targeting respiratory infectious diseases and GI o...
10-13 12:45
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Silo Pharma has completed a registered direct offering, selling 2,857,143 shares at $0.875 per share and issuing warrants for the same number of shares at $0.75, raising approximately $2.5 million. Proceeds will support working capital and general corporate purposes. The offering is led by H.C. Wainwright as placement agent. The company focuses on innovative therapies for underserved conditions like PTSD, chronic pain, and CNS disorders.
09-30 12:02
Salarius Pharmaceuticals Amends Merger Terms With Decoy To Set $10.50 Baseline Conversion Price, $3.75 Floor Price For Preferred Stock
As previously disclosed, Salarius Pharmaceuticals, Inc. (the "Company") entered into an Agreement and Plan of Merger dated January 10, 2025, as previously amended by the First Amendment on March 28, 2025, by the Second
09-18 19:09
Salarius Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Salarius Pharmaceuticals (NASDAQ:SLRX) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement. As disclosed on August 27, Salar...
09-09 20:09
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Salarius Pharmaceuticals regained compliance with Nasdaq's Minimum Bid Price Requirement and must meet the Equity Standard Requirement by October 20, 2025. The company is under a one-year monitor. Salarius also announced a merger with Decoy Therapeutics to form a new company focused on peptide conjugate therapeutics targeting respiratory infectious diseases and GI oncology. Salarius' SP-3164 will be integrated into PROTACs. The combined company p...
09-09 12:00
Decoy Therapeutics Reports Financial Downturn Amid Funding Challenges
An announcement from Salarius Pharmaceuticals ( ($SLRX) ) is now available. Dec...
08-23 05:53
Salarius Pharmaceuticals Appoints New Acting CEO
Salarius Pharmaceuticals ( ($SLRX) ) just unveiled an announcement. On August 1...
08-18 20:59
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Celestica Inc. (NYSE:CLS) rose sharply in pre-market trading after th...
07-29 18:46
